Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:


UK research unveils new generation of immunological adjuvants


Investment from the White Rose Technology Seedcorn Fund (WRTSF) - the venture capital fund owned by the universities of Leeds, Sheffield and York (UK) - has funded the completion of a series of significant technical milestones in the development of a new family of `immunologically-rational` adjuvants for vaccines, which are materially very different from the existing adjuvants based on aluminium salts and bacterial cell wall components.

Sheffield-based life science company Adjuvantix Ltd is now well positioned in its ambition to enter the $5 billion vaccine market(i).

The patented technology produces adjuvants that have greater effectiveness and no harmful side effects - addressing the key hurdles(ii) that have been preventing the development of vaccines for the infectious diseases such as hepatitis-B, hepatitis-C and HIV. Moreover the novel adjuvants should enable a new generation of therapeutic and prophylactic vaccines for chronic, non-infectious diseases such as diabetes, multiple sclerosis and stroke.

The company is based on the research in the University of Sheffield`s Department of Genomic Medicine and has already attracted significant interest from a number of pharmaceutical companies.

Dr. Peter Laing, formerly Research Director at Actinova Ltd and SynGenix Ltd has been appointed as a non-executive director to the company, and David Gough, formerly Chief Executive of Avlar BioVentures has been appointed as consultant to the management team in preparation for the next round of funding.

Peter Laing said
"The Adjuvantix technology is extremely exciting and will be a key enabler in the race to develop new vaccines based upon developments in genomics. "

The company is currently focusing on developing adjuvants for vaccines to prevent and treat Alzheimer`s disease, influenza, meningitis and herpes virus infection - each chosen to represent a specific area of Adjuvantix expertise.

David Gough | alfa

More articles from Health and Medicine:

nachricht NIH scientists describe potential antibody treatment for multidrug-resistant K. pneumoniae
14.03.2018 | NIH/National Institute of Allergy and Infectious Diseases

nachricht Researchers identify key step in viral replication
13.03.2018 | University of Pittsburgh Schools of the Health Sciences

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Tiny implants for cells are functional in vivo

For the first time, an interdisciplinary team from the University of Basel has succeeded in integrating artificial organelles into the cells of live zebrafish embryos. This innovative approach using artificial organelles as cellular implants offers new potential in treating a range of diseases, as the authors report in an article published in Nature Communications.

In the cells of higher organisms, organelles such as the nucleus or mitochondria perform a range of complex functions necessary for life. In the networks of...

Im Focus: Locomotion control with photopigments

Researchers from Göttingen University discover additional function of opsins

Animal photoreceptors capture light with photopigments. Researchers from the University of Göttingen have now discovered that these photopigments fulfill an...

Im Focus: Surveying the Arctic: Tracking down carbon particles

Researchers embark on aerial campaign over Northeast Greenland

On 15 March, the AWI research aeroplane Polar 5 will depart for Greenland. Concentrating on the furthest northeast region of the island, an international team...

Im Focus: Unique Insights into the Antarctic Ice Shelf System

Data collected on ocean-ice interactions in the little-researched regions of the far south

The world’s second-largest ice shelf was the destination for a Polarstern expedition that ended in Punta Arenas, Chile on 14th March 2018. Oceanographers from...

Im Focus: ILA 2018: Laser alternative to hexavalent chromium coating

At the 2018 ILA Berlin Air Show from April 25–29, the Fraunhofer Institute for Laser Technology ILT is showcasing extreme high-speed Laser Material Deposition (EHLA): A video documents how for metal components that are highly loaded, EHLA has already proved itself as an alternative to hard chrome plating, which is now allowed only under special conditions.

When the EU restricted the use of hexavalent chromium compounds to special applications requiring authorization, the move prompted a rethink in the surface...

All Focus news of the innovation-report >>>



Industry & Economy
Event News

Virtual reality conference comes to Reutlingen

19.03.2018 | Event News

Ultrafast Wireless and Chip Design at the DATE Conference in Dresden

16.03.2018 | Event News

International Tinnitus Conference of the Tinnitus Research Initiative in Regensburg

13.03.2018 | Event News

Latest News

Earlier flowering of modern winter wheat cultivars

20.03.2018 | Agricultural and Forestry Science

Smithsonian researchers name new ocean zone: The rariphotic

20.03.2018 | Life Sciences

Molecular doorstop could be key to new tuberculosis drugs

20.03.2018 | Life Sciences

Science & Research
Overview of more VideoLinks >>>